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We investigate the relation between diabetes mellitus and risk of prostate cancer among older (age 65–79 years) men in a
population-based case–control study of 407 incident histologically confirmed cases registered in the South Carolina Central Cancer
Registry between 1999 and 2001 (70.6% response rate); controls were 393 men identified through the Health Care Financing
Administration Medicare beneficiary file for South Carolina in 1999 (63.8% response rate). After adjusting for age, race, and prostate
cancer screening in the past 5 years, a history of diabetes mellitus was associated with a reduced risk of prostate cancer (adjusted
odds ratio (aOR)¼0.64; 95% confidence interval (CI)¼0.45, 0.91). The protective effect was stronger for those with complications
associated with diabetes (aOR¼0.61; 95% CI¼0.42, 0.90) and for African-American men (aOR¼0.36; 95% CI¼0.21, 0.62).
Additional research is needed to understand the biologic mechanisms by which diabetes may influence prostate cancer risk; genetic
factors may play an important role in understanding this association.
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Four prospective studies (Thompson et al, 1989; Adami et al,
1991; Giovannucci et al, 1998; Weiderpass et al, 2002) and one
hospital-based case–control study (Rosenberg et al, 2002) have
found a reduced risk of prostate cancer associated with type II
diabetes mellitus. The cohort studies suggest that risk of prostate
cancer decreases with increasing time since diabetes diagnosis.
Detection bias, potentially introduced if those with diabetes
are more likely to receive prostate cancer screening, does not
appear to explain the association (Giovannucci, 2001). These
findings contrast with three additional prospective (Coughlin et al,
1996; Will et al, 1999; Gapstur et al, 2001) and three case–control
studies (Mishina et al, 1985; LaVecchia et al, 1994; Tavani et al,
2002) that did not find an association between diabetes and
prostate cancer.
Giovannucci (2001) suggested that future studies investigate: (1)
the time lag between diabetes mellitus diagnosis and subsequent
prostate cancer; (2) diabetes complications and prostate cancer
risk; and (3) any association between diabetes and stage of prostate
cancer at detection. The purpose of this analysis was to investigate
the association between diabetes mellitus and prostate cancer
among African-American and Caucasian men in a population-
based case–control study.
MATERIALS AND METHODS
Details of this population-based case–control study have
been reported elsewhere (Sanderson et al, 2004). Briefly,
cases aged 65–79 years diagnosed with primary invasive
histologically confirmed prostate cancer between October 1999
and September 2001 were identified through the South Carolina
Central Cancer Registry (SCCCR). During the study period, a total
of 551 Caucasian men and 245 African-American men with
localised disease (stages I and II), and 98 Caucasian men and 70
African-American men with advanced disease (stages III and IV)
reported to the SCCCR were eligible. All eligible cases with
advanced disease, and a random sample of men with localised
disease within 5-year age groups (42% of Caucasian cases and 83%
or African-American cases) were selected. A total of 426 prostate
cancer cases (70.6% of eligible cases) completed a standardised
telephone interview. Of potentially eligible cases, 71 refused
(11.8%), 24 died prior to the interview (4.0%), 59 were not located
(9.8%), and 23 were too sick to participate (3.8%). After
eliminating seven prevalent prostate cancer cases and 11 cases
who did not provide complete interview data, 407 cases remained
for analyses.
Control subjects were South Carolina residents aged
65–79 years randomly sampled from the 1999 Health Care
Financing Administration (HCFA) Medicare beneficiary file.
They were frequency matched to cases on age (5-year age groups),
race (Caucasian, African-American), and geographical region
(western, middle and eastern third of the state). A total of
482 control subjects (63.8%) completed the interview. Of
potentially eligible controls, 108 refused (14.3%), 22 died prior
to the interview (2.9%), 112 were not located (14.8%), and 32
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controls with prevalent prostate cancer and 37 controls
whose interviews were incomplete, 393 controls remained for
analysis.
Cases and controls were recruited through mailings
that described the study and informed the potential participant
that an interviewer would call them soon. Since the HCFA file
does not contain telephone numbers, controls whose phone
numbers could not be located through directory assistance,
telephone, or reverse directories were sent an additional
letter asking for a preferred contact number. Trained interviewers
from the University of South Carolina Survey Research Laboratory
conducted computer-assisted telephone interviews with sub-
jects who provided verbal consent with the understanding that
written consent would be obtained. Telephone interviews of
30–40min in length collected information on demographic
characteristics, socioeconomic status, alcohol and tobacco
use, physical activity, diet, medical history (including diabetes,
stroke, myocardial infarction, cirrhosis or other liver
disease, hypertension, and hypercholesterolemia), family history
of cancer, history of sexually transmitted diseases, and
farm-related work activities and exposures. Men were specifically
asked if they had ever been diagnosed with diabetes mellitus
(also known as high blood sugar or sugar diabetes).
Most exposures pertained to the period prior to a reference
date, the date of diagnosis for cases and an assigned date for
controls. Institutional Review Boards of the University of South
Carolina, the Centres for Disease Control and Prevention, and the
National Cancer Institute approved this project’s data collection
procedures.
We used unconditional logistic regression to estimate the odds
ratio of prostate cancer associated with a prior history of diabetes
mellitus while controlling for potential confounding factors
(Breslow and Day, 1980). The latter included age, race, educational
level, annual income, occupation, marital status, family history of
prostate cancer, body mass index, diet, physical activity, alcohol
and tobacco use, and number of prostate cancer screenings (digital
rectal exam (DRE) or prostate-specific antigen (PSA) in the past 5
years prior to the reference date. As screening by DRE and PSA
were highly correlated (r¼0.61, Po0.0001), we created a variable
to combine the number of prostate cancer screenings in the past 5
years by DRE or PSA. Further because diabetic men may be more
frequently screened by their physicians and for diabetes, we
included prostate cancer screening in logistic models. Body mass
index, defined as self-reported weight (kg) before reference date
divided by the square of self-reported height (m
2), was included as
a continuous variable in logistic regression models and categorised
as normal weight (o25.0kgm
 2), overweight (25.0–29.9kgm
 2),
or obese (X30.0kgm
 2).
Diet, assessed in a 20-item food frequency questionnaire
adapted from Hayes et al (1999), covered foods consumed
at least once a year in the period prior to the reference date. The
animal fat food group included: eggs, whole milk, cheese,
ice cream, beef, stew, mixed meat dishes, hot dogs, luncheon
meats, bacon, other pork, liver, and chicken; the lycopene
food group included: raw tomatoes, cooked tomatoes, and
watermelon. Servings per week of food groups were categorised
into quartiles among controls. Engaging in strenuous or moderate
leisure-time physical activity for an average of one or more hours a
week since age 18 years were categorised as tertiles within the
active group.
The primary exposure, diabetes mellitus, was included as a
dichotomous variable (yes/no history of diabetes). As it has been
suggested that diabetes complications may be more strongly
associated with prostate cancer risk (Weiderpass et al, 2002), we
created a variable to indicate severe diabetes complications that
combined reported diabetes with hypertension, hypercholester-
olemia, stroke, or a myocardial infarction. Both, such men and
those with no such complications were compared to those without
diabetes.
RESULTS
The final sample included 407 prostate cancer cases (166 African-
American and 241 Caucasian men) and 393 controls (166
African-American and 227 Caucasian men). Owing to frequency
matching, cases and controls were, in general, comparable in age
and race crude odds ratios (ORs) and 95% confidence intervals
(CIs) for prostate cancer are presented Tables 1–2 for the risk
factors of interest. Having had the benign prostatic hyperplasia
(BPH) or a family history of prostate cancer was associated
with incident prostate cancer as were annual PSA tests or DRE over
the years prior to the referent date (P-value for trend o0.0001).
A history of high cholesterol was associated with reduced prostate
cancer risk (adjusted OR (aOR)¼0.72; 95% CI¼0.53, 0.96).
No other risk factors were associated with prostate cancer risk in
these data.
Presented in Table 2 are the multivariate odds ratios for diabetes
and prostate cancer risk. Our three frequency matching variables
(age, race, South Carolina region) were included in multivariate
logistic regression models as confounders as was prostate
cancer screening in the past 5 years to minimise detection
bias No other confounding factor materially affected the
OR for diabetes and prostate cancer. After adjustment, diabetes
was associated with a reduced risk of prostate cancer (aOR¼0.64;
95% CI¼0.45, 0.91) more marked among those with complica-
tions.
Table 3 presents the association between diabetes and prostate
cancer among selected prostate cancer risk factor strata. In
general, the reduced risk of prostate cancer associated with
diabetes was statistically significant for those with localised disease
and among younger men (aged 65–69 years), African-American
men, men without a family history of prostate cancer, and those
with no history of BPH.
DISCUSSION
Our findings are consistent with four prospective studies
(Thompson et al, 1989; Adami et al, 1991; Giovannucci et al,
1998; Weiderpass et al, 2002) and one hospital-based case–control
study (Rosenberg et al, 2002) that reported a reduced risk of
prostate cancer associated with diabetes mellitus. We adjusted
for prostate cancer screening to reduce detection bias since
diagnosed diabetics would typically be screened more frequently
than nondiabetics. Our findings concur with others (Giovannucci,
2001) that detection bias does not appear to explain the reduced
risk of prostate cancer associated with diabetes. When we used
the same definition of later stages (II–IV) as in a New York
hospital-based study (Rosenberg et al, 2002), our results (aOR 0.6;
95% CI¼0.5, 0.9) are consistent with those reported (0.5;
95% CI¼0.2–0.9) for diabetes and prostate cancer. Our
finding that this risk was present only among African-American
men also contrasts with a previous report (Rosenberg et al,
2002) that Hispanic and Caucasian men, yet not African-
American men, were at reduced risk of prostate cancer. Our
finding of a stronger association among those with diabetic
complications is consistent with a large cohort study (Weiderpass
et al, 2002).
It is plausible that diabetes mellitus might increase or reduce the
risk of subsequent prostate cancer incidence based on different
biologic mechanisms. Diabetes results in higher circulating insulin
and glucose levels and perhaps higher free insulin-like growth
factor I (Giovannucci, 2001), which may be growth enhancing and
therefore increase prostate cancer risk. While hyperglycemia may
be growth enhancing, androgen levels are lower in severe diabetes
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on the Leydig cells of the testis.
Our study has several limitations. We do not have data on the
age at first diabetes diagnosis and so cannot confirm reports that
Table 1 Comparison of cases and controls for demographic and other
risk factors for prostate cancer
Cases (n¼407) Controls (n¼393)
Risk factor N (%) N (%)
Age (years)
a
65–69 192 (46.2%) 186 (43.4%)
70–74 134 (32.2%) 125 (29.1%)
75–79 90 (21.6%) 118 (27.5%)
Race
a
African-American 171 (41.1%) 171 (39.9%)
Caucasian 245 (58.9%) 258 (60.1%)
Education
a
Less than 8th grade 106 (25.7%) 89 (20.8%)
oHigh school graduate 55 (13.4%) 69 (16.1%)
High school graduate 101 (24.5%) 102 (23.8%)
Some college or technical school 54 (13.1%) 77 (18.0%)
College graduate 96 (23.3%) 92 (21.5%)
Missing 4 0
P-value for trend 0.41
Annual income
o$20000 122 (34.4%) 106 (32.0%)
$20000–$29999 72 (20.3%) 58 (17.5%)
$30000–$39999 42 (11.8%) 54 (16.3%)
$40000–$49999 25 (7.0%) 36 (10.9%)
$50000 or more 94 (26.5%) 77 (23.3%)
Missing 52 62
P-value for trend 0.69
Marital status
Single/separated/divorced/widowed 73 (18.2%) 80 (20.6%)
Married/living as married 328 (81.8%) 308 (79.4%)
Missing 6 5
BMI (kgm
 2)
Normal weight (p24.9 BMI) 105 (26.5%) 113 (29.5%)
Overweight (25.0–29.9 BMI) 198 (50.0%) 175 (45.7%)
Obese (X30.0 BMI) 93 (23.5%) 95 (24.8%)
Missing 11 10
P-value for trend 0.75
Family history of prostate cancer
Yes 120 (30.2%)* 60 (15.4%)
No 278 (69.8%) 329 (85.6%)
Missing 9 4
History of benign prostatic hyperplasia
Yes 159 (39.7%)* 102 (26.2%)
No 242 (60.3%) 288 (73.8%)
Missing 6 3
History of high cholesterol
Yes 122 (30.6%)** 147 (38.2%)
No 277 (69.4%) 238 (61.8%)
Missing 8 8
History of hypertension
Yes 210 (52.2%) 206 (53.4%)
No 192 (47.8%) 180 (46.6%)
Missing 5 4
Prostate cancer screening (#of PSAs or DREs in the past 5 years)
a
0 30 (7.4%) 57 (13.7%)
1–2 44 (10.9%) 57 (13.7%)
3–4 52 (12.9%) 66 (15.9%)
5–6 73 (18.1%) 83 (20.0%)
7–8 52 (12.9%) 49 (11.8%)
9–10 152 (37.7%) 104 (25.0%)
Missing 13 13
P-value for trend o0.0001
Table 1 (Continued)
Cases (n¼407) Controls (n¼393)
Risk factor N (%) N (%)
Drinking duration (years)
0 130 (33.7%) 110 (30.2%)
o25 75 (19.4%) 74 (20.3%)
25–45 94 (24.4%) 87 (23.9%)
445 87 (22.5%) 93 (25.6%)
Missing 21 29
P-value or trend 0.29
Smoking duration (years)
0 106 (26.5%) 116 (30.1%)
o25 116 (29.0%) 109 (28.3%)
25–45 103 (25.8%) 93 (24.2%)
445 75 (18.8%) 67 (17.4%)
Missing 7 8
P-value or trend 0.30
Consumption of animal fat (quartiles)
p12.7 102 (28.3%) 85 (25.0%)
12.8–18.95 82 (22.7%) 85 (25.0%)
18.96–26.7 92 (25.8%) 83 (24.4%)
X26.8 85 (23.6%) 87 (25.0%)
Missing 46 53
P-value or trend 0.46
Consumption of lycopene (quartiles)
p2.6 98 (26.7%) 86 (24.6%)
2.7–4.5 97 (26.4%) 85 (24.4%)
4.6–8.0 96 (26.2%) 80 (22.9%)
X8.1 76 (20.7%) 98 (28.1%)
Missing 40 44
P-value for trend 0.11
Strenuous or moderate physical activity (tertiles among active)
None 67 (17.9%) 69 (19.6%)
o4.0 53 (14.2%) 52 (14.8%)
4.0–12 109 (29.1%) 109 (31.0%)
412 145 (38.8%) 122 (34.7%)
Missing 33 41
P-value for trend 0.33
*Po0.01; **P¼0.01–0.05. BMI¼body mass index; PSA¼prostate-specific antigen;
DRE¼digital rectal exam.
Table 2 OR for prostate cancer and diabetes among men aged 65–79
years
Case,
N¼407
Control,
N¼393
Adjusted
a
OR (95% CI)
History of diabetes
Missing 7 4
No 330 (82.1%) 289 (74.3%) 1.00 (REF)
Yes 72 (17.9%) 100 (25.7%) 0.64 (0.45, 0.91)
No complications 14 (3.5%) 17 (4.4%) 0.79 (0.37, 1.67)
With complications 58 (14.4%) 83 (21.3%) 0.61 (0.42, 0.90)
aAdjusted for age (categorical variable), race (African-American compared with
Whites), South Carolina region (three areas), and prostate cancer screening in the
past 5 years before the referent date (yes annual screening vs no). OR¼odds ratios;
CI¼confidence interval.
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shows a stronger association (Giovannucci et al, 1998; Tavani et al,
2002). Given the age range of subjects (65–79 years) and the mean
age of diabetes diagnosis in the USA of 46.5 years (http://
www.cdc.gov/diabetes/statistics), it is likely that the majority of
subjects reporting diabetes had had this condition for at least 10
years. Diabetes was self-reported and we do not have the data to
confirm the diagnosis. However, the prevalence among Caucasian
men aged 65–79 years reported in this study (16%) was
comparable to that reported by South Carolina in 2000 as part of
a Centers for Disease Control (CDC) diabetes prevalence study
(15.4%) (Centers for Disease Control and Prevention, 2000).
Similarly, our diabetes prevalence of 29% among older African-
American men is consistent with CDC prevalence data (http://
www.cdc.gov/diabetes/statistics/prev/state). Other limitations in-
clude a lower response rate among African-Americans than
Caucasians. The refusal rates did not differ by race, but the
proportion that could not be located was higher among African-
American (19.3%) than Caucasian (6%) cases and controls.
Another source of misclassification was the memory problems
common among older men; this misclassification was likely
nondifferential, thereby reducing our ability to identify weak
associations.
This is the first population-based case–control study to
address diabetes and prostate cancer risk among both African-
American and Caucasian men. Few studies have included sufficient
numbers of African-American men (Rosenberg et al, 2002) to
determine whether they are at reduced risk of prostate cancer if
they have a history of diabetes. Hospital- and clinic-based studies
of the matter may bias the OR toward a protective effect, since
such controls may be more likely to have diabetes or have its
complications. Our finding of a reduced risk of diabetes in a
population-based study provides additional evidence that the
association is not due to such a selection bias. South Carolina has
had one of the highest incidence rates of prostate cancer (US
Cancer Statistics Working Group, 2002) and African-American
men are at significantly greater risk than their Caucasian
counterparts (Ries et al, 2003). Genetic factors that may differ
markedly by race and ethnicity may be an explanation for our
finding of a protective effect only in African-American men. Other
explanations include racial differences in health care. An under-
standing of this association may be helpful in prostate cancer
prevention efforts.
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